0001493152-26-016297
SEC filingAgape ATP Corporation's fiscal 2025 was defined by a challenging divergence: revenue growth was overshadowed by a deepening operating loss, as strategic diversification into new business lines pressured profitability and increased cash consumption.
Revenue for fiscal 2025 was $1.5 million, representing a 15.2% increase from the prior year. This growth occurred despite management's commentary indicating a revenue decrease in the provision of complementary health therapies business, attributed to lower revenue generated from overseas customers compared to previous years. Gross profit grew 10.4% to $838.3 thousand, resulting in a gross margin of 55.0%. Management has stated that the decrease in gross profit margin was due to low gross profit margin in green energy operations, highlighting the margin pressure from the company's strategic diversification.
Operating income was -$3.3 million, a 26.6% decline from the prior year, resulting in an operating margin of -213.7%. This significant operating loss reflects the cost challenges associated with the company's business mix. Management has cited multiple factors contributing to increased costs, including inventory write-offs and write-downs in the network marketing business, varying gross profit margins in complementary health therapies operations, and costs from green energy operations. Furthermore, the increase in general and administrative expenses was attributed to higher professional fees. These factors collectively eroded operating profitability despite the top-line growth.
Net income was -$2.3 million, an improvement of 7.7% from the prior year's net loss. However, diluted earnings per share was -$2.85, a substantial deterioration from -$0.63 in the prior year. This divergence between the net income trend and the per-share metric warrants investor attention regarding the capital structure and share count implications.
Net cash used in operating activities was -$2.4 million, indicating ongoing operational cash consumption. The company's business model, which involves network marketing, complementary health therapies, and green energy operations, requires careful management of working capital and investment. Management's operational commentary regarding inventory obsolescence reviews and the varying cost structures across business lines suggests ongoing challenges in optimizing cash conversion cycles.
The company operates in segments focused on stimulating ATP production for metabolic health, network marketing, and green energy. Management's discussion highlights the operational complexities of this diversified model, including inventory management challenges and varying margin profiles. The strategic shift into green energy, while a growth initiative, has introduced low-margin operations that are pressuring overall profitability. Management acknowledges in risk factors that growth initiatives may not be successfully completed or may be more costly than anticipated, which is relevant given the current margin compression and operating losses. The company's internal focus on capitalizing costs for internal-use software only when specific criteria are met reflects a disciplined approach to investment amid these financial challenges.